CHARLES SCHWAB INVESTMENT MANAGEMENT INC - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 256 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.1%.

Quarter-by-quarter ownership
CHARLES SCHWAB INVESTMENT MANAGEMENT INC ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$14,143,246
-18.7%
396,725
+5.2%
0.00%
-20.0%
Q2 2023$17,401,989
+17.0%
377,238
+1.7%
0.01%0.0%
Q1 2023$14,875,576
-13.8%
370,962
-0.4%
0.01%
-16.7%
Q4 2022$17,247,454
+14.1%
372,274
+2.0%
0.01%
+20.0%
Q3 2022$15,120,000
-54.0%
365,106
-33.8%
0.01%
-54.5%
Q2 2022$32,881,000
-16.3%
551,126
+1.9%
0.01%
-8.3%
Q1 2022$39,269,000
-11.3%
540,744
+2.8%
0.01%
-7.7%
Q4 2021$44,247,000
-4.5%
526,183
+2.4%
0.01%
-13.3%
Q3 2021$46,345,000
-2.2%
513,849
+3.4%
0.02%
-6.2%
Q2 2021$47,399,000
-30.6%
497,101
-17.1%
0.02%
-36.0%
Q1 2021$68,252,000
-9.2%
599,431
+10.3%
0.02%
-16.7%
Q4 2020$75,206,000
+85.9%
543,274
+10.4%
0.03%
+57.9%
Q3 2020$40,454,000
+38.0%
492,194
+31.3%
0.02%
+35.7%
Q2 2020$29,317,000
+92.3%
374,792
+9.2%
0.01%
+55.6%
Q1 2020$15,244,000
+6.4%
343,099
+2.2%
0.01%
+12.5%
Q4 2019$14,333,000
+1.6%
335,579
+1.8%
0.01%0.0%
Q3 2019$14,105,000
-30.2%
329,693
+3.5%
0.01%
-33.3%
Q2 2019$20,220,000
-3.2%
318,418
+5.8%
0.01%
-7.7%
Q1 2019$20,878,000
+83.5%
301,003
+15.1%
0.01%
+44.4%
Q4 2018$11,375,000
-42.3%
261,611
+1.3%
0.01%
-30.8%
Q3 2018$19,717,000
+4.8%
258,277
+5.5%
0.01%
-7.1%
Q2 2018$18,812,000
+65.3%
244,720
+9.7%
0.01%
+55.6%
Q1 2018$11,379,000
+42.2%
223,154
+29.3%
0.01%
+50.0%
Q4 2017$8,003,000
-17.2%
172,539
-4.9%
0.01%
-25.0%
Q3 2017$9,666,000
-29.1%
181,470
-17.3%
0.01%
-38.5%
Q2 2017$13,628,000
-5.1%
219,415
+3.6%
0.01%
-7.1%
Q1 2017$14,356,000
+2.7%
211,797
+6.5%
0.01%
-6.7%
Q4 2016$13,980,000
+6.9%
198,821
+7.8%
0.02%0.0%
Q3 2016$13,083,000
+56.6%
184,412
+8.0%
0.02%
+50.0%
Q2 2016$8,355,000
-21.8%
170,806
+1.2%
0.01%
-28.6%
Q1 2016$10,683,000
-38.1%
168,735
+9.7%
0.01%
-39.1%
Q4 2015$17,252,000
+25.9%
153,788
+8.1%
0.02%
+15.0%
Q3 2015$13,705,000
+44.4%
142,291
+53.6%
0.02%
+53.8%
Q2 2015$9,488,000
+188.7%
92,657
+75.1%
0.01%
+160.0%
Q1 2015$3,287,000
+79.8%
52,928
+27.1%
0.01%
+66.7%
Q4 2014$1,828,000
-17.8%
41,644
+6.1%
0.00%
-25.0%
Q3 2014$2,223,000
+233.8%
39,268
+164.8%
0.00%
+300.0%
Q2 2014$666,000
+170.7%
14,828
+195.1%
0.00%
Q1 2014$246,0005,0240.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q4 2020
NameSharesValueWeighting ↓
EcoR1 Capital, LLC 497,899$31,617,0003.20%
HIGHLINE CAPITAL MANAGEMENT, L.P. 390,453$24,794,0001.81%
First Light Asset Management, LLC 180,017$11,431,0001.59%
Rock Springs Capital Management LP 580,000$36,830,0001.33%
Capital Impact Advisors, LLC 36,165$2,244,0000.82%
SECTOR GAMMA AS 79,653$5,058,0000.81%
Verity Asset Management, Inc. 7,193$457,0000.51%
Opus Point Partners Management, LLC 5,064$322,0000.48%
Capital International Sarl 52,000$3,302,0000.46%
PACIFIC VIEW ASSET MANAGEMENT, LLC 6,216$394,0000.43%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders